Viekirax (ombitasvir;paritaprevir;ritonavir)
- Region
- 🇪🇺 EU
- Active substance
- ombitasvir;paritaprevir;ritonavir
- Company
- AbbVie Deutschland GmbH & Co. KG
- Status
- Withdrawn
- Therapeutic area
- Hepatitis C, Chronic
- CHMP opinion
- Thu 20 Nov 2014
- EU approval
- Wed 14 Jan 2015
- Application
- EMEA/H/C/003839
- ATC
- J05AP53
- Official record
- www.ema.europa.eu
Indication
Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. For hepatitis C virus (HCV) genotype specific activity.
Regulatory milestones
No milestones recorded in the last year.
Follow Viekirax
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.